
MediWound Ltd. (NASDAQ:MDWD – Free Report) – Analysts at HC Wainwright raised their FY2026 earnings estimates for MediWound in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will post earnings per share of ($1.86) for the year, up from their prior forecast of ($2.02). The consensus estimate for MediWound’s current full-year earnings is ($1.86) per share. HC Wainwright also issued estimates for MediWound’s Q4 2026 earnings at ($0.57) EPS, Q2 2027 earnings at ($0.58) EPS, Q3 2027 earnings at ($0.50) EPS, Q4 2027 earnings at ($0.45) EPS, FY2027 earnings at ($2.07) EPS, FY2028 earnings at ($1.18) EPS and FY2029 earnings at $0.51 EPS.
MediWound (NASDAQ:MDWD – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.06. MediWound had a negative net margin of 234.98% and a negative return on equity of 61.68%. The business had revenue of $3.57 million during the quarter, compared to the consensus estimate of $6.73 million.
Check Out Our Latest Stock Report on MediWound
MediWound Stock Down 0.5%
Shares of MDWD stock opened at $13.61 on Tuesday. The stock’s fifty day moving average price is $13.21 and its two-hundred day moving average price is $14.99. MediWound has a fifty-two week low of $11.80 and a fifty-two week high of $19.70.
Insider Transactions at MediWound
In related news, COO Shmuel Hess sold 3,958 shares of the stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $12.92, for a total value of $51,137.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 9.20% of the stock is currently owned by corporate insiders.
Institutional Trading of MediWound
A hedge fund recently bought a new position in MediWound stock. Marshall Wace LLP purchased a new position in shares of MediWound Ltd. (NASDAQ:MDWD – Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,026 shares of the biopharmaceutical company’s stock, valued at approximately $207,000. Marshall Wace LLP owned approximately 0.12% of MediWound as of its most recent filing with the Securities and Exchange Commission (SEC). 46.83% of the stock is currently owned by institutional investors.
About MediWound
MediWound Ltd. is an Israeli biotechnology company that develops topical enzymatic treatments for tissue repair. Its products are designed to remove damaged tissue and support care for patients with burns and chronic wounds. The company’s lead product, NexoBrid, is a bromelain-based treatment used to remove dead tissue from deep thermal burns. It has received regulatory approvals in the United States and other markets. In the United States, MediWound works with Vericel to commercialize the product.
Recommended Stories
- Five stocks we like better than MediWound
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
